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Abstract Stroke is the third leading cause of death
worldwide after heart disease and all forms of cancers.
Monogenic disorders, genetic, and environmental risk
factors contribute to damaging cerebral blood vessels and,
consequently, cause stroke. Developments in genomic
research led to the discovery of numerous copy number
variants (CNVs) that have been recently identified as a new
tool for understanding the genetic basis of many diseases.
This review discusses the current understanding of the
types of stroke, the existing knowledge on the involvement
of specific CNVs in stroke as well as the limitations of the
methods used for detecting CNVs like SNP-microarray. To
confirm an unequivocally association between CNVs and
stroke and extend the current findings, it would be desirable
to use another methodology to detect smaller CNVs or
CNVs in genomic regions poorly covered by this tech-
nique, for instance, CGH-array.
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Introduction
Stroke is the third leading cause of death worldwide after
heart disease and all forms of cancers. Each year about
795,000 people in the USA suffer from a recurrent or new
stroke [1]. This pathology is one of the leading contributors
to death and long-term adult disability worldwide, and for
this reason, the burden of stroke is felt physically, socially,
economically, and emotionally by patients, by their rela-
tives and health care services [2]. Stroke is defined as a
syndrome characterized by a quick development of clinical
signs and loss of cerebral functions, with symptoms lasting
for over 24 h or leading to death, with an apparent cause of
vascular origin [3].
Conventional and genetic risk factors contribute to
damaging a cerebral blood vessel and, consequently, cause
stroke [4]. Genetics plays a significant role in the devel-
opment of this disease. In fact, several monogenic disor-
ders cause stroke, as well as the interaction of multiple
genes.
A new form of genetic variation, known as copy number
variations (CNVs), has been recently identified as a new
tool for understanding the genetic basis of many diseases,
including stroke. CNVs are deletions and duplications (loss
or gain) of segments of genome [5, 6].
CNV may alter the levels of gene expression, may also
disrupt genes or regulation elements, may lead to frame-
shifts, and may generate new fusion products; all these
genetic variations can result in a phenotypic variation,
susceptibility of an individual to disease and/or a differ-
entiated drug response [7, 8].
Today, modern high-resolution technologies, such as
comparative genome hybridization (CGH) arrays, allow to
detect simultaneously CNVs in multiple loci. These tech-
nologies may be clinically used to identify people who may
be at risk for a stroke or might create benefit to identify
specific therapies.
This review aims to provide a comprehensive overview
of stroke types and their etiopathogenesis and summarize
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Stroke types
Occluded or ruptured cerebral blood vessel determines a
reduction in normal cerebral blood flow in the affected
vascular territory, resulting in reduced nutrient delivery to
gray and white matter [9]. Without oxygen and nutrients
from blood, neurons start to die within a few minutes in the
core of the infarcted area. The region around the core,
called ‘‘the ischemic penumbra,’’ contains functionally
impaired cells but still viable for the presence of collateral
vessels. This area may become infarcted at later time points
due to secondary neuronal damage caused by the cascade
of biochemical events that occurs after ischemia. This
mechanism is common to all types of stroke: ischemic
stroke (IS) [2], hemorrhagic stroke (HS), and transient
ischemic attack (TIA).
IS represents up to 80 % of all stroke cases reported in
epidemiological studies [2]. It is more often disabling
rather than fatal, representing the most common life
threatening neurological disorder. The remaining 20 % of
stroke cases are caused by primary intracerebral hemor-
rhage (about 15 %) and subarachnoid hemorrhage (about
5 %) with a potential mortality rate from 30 to 50 % within
30 days [10, 11]. Last, TIA is similar to IS but differs in
duration (less than 24 h).
This distinction in different stroke types is critical for
therapeutic decision, although it is likely that these forms
of stroke have both similar and different genetic suscepti-
bility, risk factors, and etiologic overlaps. Furthermore, the
patients’ global risk factor profile at the time of the stroke
may influence the form of stroke that occurs.
Risk factors
Stroke is a challenging disease to study, because it can
depend on a wide variety of risk factors. Conventional risk
factors that increase a person’s likelihood of having a
stroke can be controllable and uncontrollable (Fig. 1) [12].
Controllable risk factors, by medication or lifestyle
changes, primarily include high blood pressure, diabetes
mellitus, carotid artery stenosis, peripheral artery disease,
atrial fibrillation, stress, alcohol, drug abuse, hypercholes-
terolemia, obesity, smoking, and physical inactivity.
Uncontrollable risk factors mainly comprise age, race
(African–Americans have a much higher risk of death from
a stroke than Caucasians—http://www.strokeassociation.
org), ethnicity, family history, genetic factors, previous
stroke or TIA, artery abnormalities, fibromuscular dys-
plasia, male gender, etc. Genetic factors contributing to
onset of stroke have been identified in twin studies and
familial aggregation studies [13]. Genetic predisposition to
stroke can be categorized either as a single gene disorder or
as a polygenic disorder, although the majority of the
studies have mainly focused on monogenic forms of stroke.
A recent study demonstrates that conventional cardiovas-
cular risk factors, particularly smoking and hypertension,
have been associated with an earlier stroke onset, high-
lighting the interaction between gene and environment, and
the clinical importance of careful risk factor control even in
patients with monogenic stroke disorders [14].
Monogenic stroke diseases
The most common monogenic form is CADASIL (cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy) (OMIM 125310). It results from
mutations in the gene NOTCH3, which encodes a trans-
membrane receptor. Mutations result in an odd number of
cysteine residues within one of the 34 epidermal growth
factor (EGF)-like repeats in the extracellular amino-ter-
minal region of the Notch3 receptor, leading to its abnor-
mal accumulation at the cytoplasmic membrane of vascular
smooth muscle cells, in the vessels of patients [15].
Recently, genes involved in several other rare mono-
genic diseases have been recognized. CARASIL (cerebral
autosomal recessive arteriopathy with subcortical infarcts
and leukoencephalopathy) (OMIM 600142) causes lacunar
stroke and early onset vascular dementia, and derives from
recessive mutations in the HtrA serine protease (HTRA1)
gene, which is involved in TGF-beta signaling [16].
COL4A1 and COL4A2 are two genes that encode the
alpha 1 and alpha 2 chains of type IV collagen, which
cause autosomal dominant porencephaly, infantile hemi-
paresis, and childhood hemorrhage [17, 18].
Another monogenic condition characterized by visual
loss, stroke, and dementia is autosomal dominant retinal
vasculopathy with cerebral leukodystrophies (RVCL)
(OMIM 192315), a microvascular endotheliopathy. Muta-
tions in the TREX1 gene are responsible for this disease [19].
Mutations in the genes underlying these monogenic
forms of stroke are not recognized as the cause for multi-
factorial stroke, but may help in their comprehension.
Multifactorial stroke
Single mutations can induce stroke, but in most cases, this
condition is caused by interaction among multiple genes.
Several candidate pathways have been examined in stroke,
including those involved in endothelial function, nitric
oxide production, renin–angiotensin–aldosterone system,
coagulation, haemostasis, and inflammation (Fig. 1).
Nowadays, because of the completion of Human
Genome Project, modern high-throughput technologies,
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including the next generation sequencing (NGS), CGH,
and single-nucleotide polymorphism (SNP) arrays, can
be used to genotype simultaneously multiple genes
involved in stroke. The subsections below will describe
the CNVs and the methods to detect them to assess the
potential association between CNVs and the develop-
ment of stroke.
CNV
CNVs are defined as deletions or duplications of DNA that
produce any change in copy number of a specific chro-
mosomal region [5, 6, 20]. Their size varies from one
kilobase (kb) to several megabases (Mb) [21, 22], and they
often involve one or more genes [6].
In a diploid cell, the number of copies of a locus is two,
a copy inherited from the mother and the other from the
father, but some loci may contain CNVs.
It has been estimated that about 12 % of the genome is
covered by CNVs and more than 41 % identifies CNVs
overlap with known genes [6, 23, 24]. CNVs play an
important role in the genome variability allowing humans
to evolve and adapt [6, 20, 25].
CNVs have been recognized as source of both normal
genetic variation and pathogenic mutation [26]. They can
destroy regulation elements, generating new fusion prod-
ucts with various possible positive or negative
Fig. 1 Several pathogenetic
mechanisms and a wide variety
of risk factors can be correlated
with stroke onset such as those
indicated in the image
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consequences [20, 27]. Other studies indicate that larger
CNVs are associated with pronounced clinical character-
istics and deletions are associated with more severe phe-
notypes than duplications [6, 7].
CNVs may be divided into inherited or de novo types,
and this depends on whether they are transmitted or not by
at least one parent [28].
CNVs are classified into different categories (Table 1).
Common CNVs usually represent normal genomic varia-
tion or benign. Rare CNVs can be likely benign variant
specific to an individual or family, pathogenic variant,
likely pathogenic variant and variant of unknown signifi-
cance (VOUS)–CNVs with uncertain clinical and func-
tional relevance. VOUS occur when a new CNV is
identified. Family studies may help clinical interpretation,
because the presence of a de novo CNV that segregates
with the pathological phenotype strengthens the evidence
that it is pathogenic. However, the importance of some
CNVs may be still uncertain even after studies on families
because of their variable expressivity; for this reason, it is
extremely useful to perform comparative case–control data
analysis in large populations to definitively associate
specific CNVs to human diseases. Some CNVs do not lead
to phenotypic effect in the carrier, but they can create
genomic instability in future generations [20]. Normal
genomic variants or benign CNVs may sometimes indi-
rectly cause or contribute to pathogenicity, for instance, if:
• each parent takes the same heterozygous deletion on an
allele, hence, two benign heterozygous deletions gen-
erating a deleterious homozygous deletion;
• each parent has a different, benign heterozygous
deletion in the same gene, when both parental muta-
tions are inherited, they cause a deleterious effect in the
offspring;
• CNV on the X chromosome in an unaffected mother
can be deleterious when inherited by a son [29, 30];
• there is a deletion on one allele and a mutated gene on
the other allele [31];
• the CNV occurs in combination with another CNV and
this leads to a pathogenic effect [32].
For all these reasons, a better understanding of all
mechanisms underlying CNVs is required.
Methods to detect CNVs
Different methods for detecting CNVs are available,
including real-time PCR (RT-PCR), NGS, and microar-
rays. The last one is now the primary method used for
CNVs detection.
Microarrays include both SNP- and CGH-arrays. These
technologies allow detection of CNVs at higher resolution
than classical cytogenetic methods [5, 33]. The application
of CGH- and SNP-arrays in control cohorts produces a
genome-wide architecture of CNVs named ‘‘CNV land-
scape’’ [26, 34].
Array-based technologies have emphasized recurrent
CNVs that seem to be associated with some diseases; in
effect, they have been identified more frequently in patients
compared with control populations.
All these methods differ in their ability to detect dele-
tions or duplications; for instance, more duplications are
missed by SNP-array and NGS approaches than by CGH-
array. Currently, CGH-array is the most sensitive tool for
the research of small differences in CNVs [35].
CGH-array allows to detect chromosome imbalances too
tiny to be seen with the microscope. DNA samples from a
patient and from a control are labeled with two different
fluorophores and, consequently, hybridized on array con-
taining thousands of known DNA probes. The probes are
arranged in a precise grid on a glass slide called ‘‘chip’’
[36, 37]. The most commonly used fluorochromes are red
and green (cyanine 5 and cyanine 3). The chip is analyzed
in a microarray scanner which measures the amount of red
and green fluorescence on each probe. Last, an array ana-
lytical software calculates the ratio of fluorescence and in
this way deletions or duplications in DNA can be identified
(Fig. 2).
CNVs in ischemic stroke
CNVs are associated with several complex disorders, and
their potential association with risk for stroke has been
object of lively discussion [38].
Until now, there are a relatively few association studies
between CNVs and patients with IS.
In the first, genome-wide analysis was investigated
whether CNVs could modulate risk for IS and was intended
to provide a list of CNVs in IS patients, but no common
genomic structural variation unequivocally linked to IS
was detected [39]. CNVs were examined in 263 patients
with IS and 275 neurologically normal controls using SNP
chips (Illumina Inc., CA, USA). In 146 patients, the authors
identified a total of 231 CNVs resulting in simple deletions
or duplications. Most of the same CNVs were identified in
Table 1 CNV classification in human genome
Type CNV CNV classification
Common Benign CNV
Rare Likely benign CNV
CNV of uncertain clinical relevance
CNV of possible clinical relevance
CNV of clinical relevance
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healthy individuals too. Forty-five CNVs (19.5 %) were
unique (Table 2). Within these new potential sites of
structural variation, only one genomic region, on chromo-
some 1, contained recurrent CNVs in three individuals with
IS. These individuals showed an apparently identical
duplication spanning the genes SPRY domain-containing
SOCS box protein 1 (SPSB1) and hexose-6-phosphate
dehydrogenase (H6PD). Because of the potential clinical
relevance of these alterations, they examined copy number
at this locus in an additional 450 neurologically normal
samples. These data showed the presence of CNVs at this
locus in five of these samples (*1 %), suggesting that
these variants were not a risk factor for IS. The remaining
CNVs could have a role in the pathobiology of IS; how-
ever, due the low frequency of each individual alteration,
screening of these variants in a greater cohort would be
required to confirm the association unequivocally. In
addition, it would be desirable to use another methodology
Fig. 2 Array CGH procedure is
characterized by the isolation of
DNA from a patient/test and
from a control/reference,
independent labeled with two
different fluorophores of
different colors (usually red-
cyanine 5 and green-cyanine 3),
and consequently, hybridized on
array containing thousands of
known probes. The probes are
arranged in a precise grid on
chip. The microarray scanner
detects the fluorescent signals
on each probe. Last, array
analytical software calculates
the log2 ratio of fluorescence
(Cy5/Cy3), and in this way,
deletions or duplications in
DNA can be identified. A higher
intensity of the test sample color
in a specific region of a
chromosome versus the control
indicates the gain of DNA of
that region, while a higher
intensity of the control sample
color versus the test sample
indicates the loss of material in
that specific region. A neutral
color (yellow when are used red
and green fluorophores)
indicates no difference between
the two samples in that location
so a normal condition
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Table 2 CNVs in stroke
Type of stroke Position
(chr: start–end)
Size (kb) CN-state Genes References
IS 1:9243800–9309900 66,1 Gain H6PD, SPSB1 Matarin et al. [35]
1:9246500–9335000 88,5 Gain H6PD, SPSB1
1:9246500–9336000 89,5 Gain H6PD, SPSB1
1:173728000–173984000 256 Gain
1:226872000–226995000 123 Gain FTHL2, RHOU
3:163361400–163421900 60,5 Gain
3:184938000–185228000 290 Gain YEATS2,MAP6D1, PARL,
LOC391598, LOC647265
3:101837000–101916300 79,3 Gain GPR128, TFG
4:14308000–14516000 208 Gain
4:100903800–100966200 62,4 Gain DAPP1
4:81604000–82138000 534 Loss C4orf22
5:75963000–76129000 166 Gain IQGAP2, F2R
5:120960000–121059000 99 Gain
6:62042000–62094400 52,4 Gain
6:96663300–96713300 50 Gain FUT9
6:124750188–124907081 156,893 Gain TCBA1
6:161565000–161770000 205 Gain AGPAT4, PARK2
6:113575000–114025000 450,000 Loss LOC643884, LOC728590
7:8174000–8470000 296 Gain ICA1, NXPH1






8:43260000–43911000 651 Gain POTE8, LOC728563
9:16949000–17061000 112 Loss
9:17588300–17623200 34,9 Gain SH3GL2
9:9465000–9563000 98 Loss
10:25999000–26066800 67,8 Gain or triplication
11:39007000–39120000 113 Gain




15:53302000–53546000 244 Gain RAB27A, PIGB, CGPG1,
MIRN628, DYX1C1,
LOC729120
15:83799700–83875900 76,2 Gain or triplication AKAP13
15:88651000–88800000 149 Gain GABARAPL3, MGC75360,
IQGAP1
18:7803000–8013000 210 Gain PTPRM
18:72553700–72598400 44,7 Gain
19:61175000–61284000 109 Gain NALP8, NALP5, LOC729982




20:51262600–51307100 44,5 Gain TSHZ2
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to detect smaller CNVs or CNVs in genomic regions
poorly covered by this technique that could confirm the risk
for IS.
Nørskov and colleagues evaluated whether CNVs in
glutathione S-transferases (GSTs) M1 and T1 genes were
associated with an increased risk of ischemic vascular
Table 2 continued
Type of stroke Position
(chr: start–end)
Size (kb) CN-state Genes References
IS Loss GSTM1, GSTT1 Nørskov et al. [36]
IS Grond-Ginsbach et al. [40]
CeAD-associated Cnvs detected in 49 patients EM?
18:59640388–59694035 54 Loss SERPINB2
4:144570037–144634141 64 Gain GAB1
12:91609585–91681005 71 Loss C12orf74, PLEKHG7
9:107430028–107517525 87 Loss FKTN, TAL2, TMEM38B
6:161612276–161734297 122 Gain AGPAT4, PARK2
3:113368966–113538579 170 Loss SLC9A10, CD200
19:52912535–53094035 182 Gain GLTSCR1, EHD2, GLTSCR2,
SEPW1, TPRX1, CRX,
SULT2A1
6:183515–671736 488 Gain EXOC2, IRF4, DUSP22,
HUS1B, AL031770
1:202619544–203219581 600 Gain PPP1R15B, PIK3C2B, MDM4,
LRRN2, NFASC
2:189109859–189763802 654 Loss GULP1, DIRC1, COL3A1,
COL5A2

















4:141190354–144311522 3121 Gain SCOC, CLGN, ELMOD2,
TBC1D9, RNF150, ZNF330,
IL15, INPP4B
CeAD-associated CNVs detected in 21 patients with EM-
8:14006431–14131717 125 125 Loss SGCZ
7:132844963–132988175 143 Loss EXOC4
10:68972491–69137046 165 Gain CTNNA3
16:11935326–12115916 181 Gain RP11-166B2.1, TNFRSF17,
RUNDC2A, SNX29,
AC00760.1
2:133324676–133563950 239 Loss NCKAP5
IS Exons 35–52 Duplication VWF Nik-Zainal et al. [41]
SAH rs1242541 Loss SEL1L Bae et al. [42]
SAH 4:153210505–153212191 1.7 Loss PET112 L, FBXW7 Bae et al. [43]
10:6265006–6267388 2.4 Gain RBM17, PFKFB3
CeAD cervical artery dissection, EM? patients with electron microscopic alterations, EM patients without electron microscopic alterations, IS
ischemic stroke, SAH subarachnoid hemorrhage
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disease (IVD) including IS [40]. GSTM1 and GSTT1
detoxify the products of oxidative stress and may protect
against atherosclerosis and IVD. Furthermore, epidemio-
logical studies hypothesized that CNVs in GSTM1 and
GSTT1 genes were associated with progressive decreases in
their catalytic activity. In addition, they may modify risk of
atherosclerosis and increase risk of IS (Table 2) [41]. The
researchers included 6.557 IVD cases and 16.502 controls
from 2 general population studies and 2 case–control
studies. To genotype for the exact number of genes copies
of GSTM1 and GSTT1, they used the RT-PCR. Principal
findings in these studies individually or combined
demonstrated CNVs in GSTM1 and GSTT1 were not
associated with the risk of IS or any ischemic vascular
event. Furthermore, the authors did not detect any associ-
ations between smoking exposure and GSTM1 and GSTT1
genotype (Table 2).
IS can also be caused by spontaneous cervical artery
dissection (CeAD), in particular in healthy young adults
[42, 43], but unfortunately the etiology of CeAD is still
unknown. A genetic predisposition seems to be associated
between CeAD and inherited microscopic and submicro-
scopic connective tissue alterations. Grond-Ginsbach and
collaborators searched for causative CNVs in patients with
and without connective tissue alterations that may predis-
pose to CeAD [44]. They included 49 non-traumatic
CeAD-patients with electron microscopic alterations
(EM? patients), 21 patients without alterations (EM-
patients), and 403 control subjects. All patients were
screened for CNVs through Affymetrix SNP6.0 microar-
rays. The authors concluded that rare genetic variants may
contribute to the pathogenesis of CeAD in particular in
EM? patients (Table 2). However, the risk for CeAD
might not be related to a single-gene or a single-genetic
pathway, but it might be associated with different genetic
variants (Table 2).
Nik-Zainal and colleagues examined a case of a 35-year-
old male with a ring chromosome 12 originally diagnosed
20 years before IS appeared [45]. CGH-array analysis
revealed a submicroscopic microdeletion and microdupli-
cation within 12p13.3 and a microdeletion in 12q24.33.
FISH analysis further revealed that in this patient, the
duplication from exons 35–52 of Von Willebrand factor
(VWF) gene was in an inverted orientation within the ring
chromosome. VWF plays a critical role in maintaining the
normal balance of the clotting cascade via multiple com-
plex interactions with factor VIII, platelets, collagen, and
subsequent degradation by a metalloprotease called
ADAMTS13 (A Disintegrin And Metalloprotease with
ThromboSpondin Type-1 Motif, 13). Partial duplication of
this gene suggests that a potential mechanism for gener-
ating a prothrombotic state may have contributed to a
premature stroke (Table 2).
CNVs in hemorrhagic stroke
At present, only two studies from the same authors reported
the relationship between CNVs and HS, in particular with
subarachnoid hemorrhage (SAH) (Table 2).
In 2008, Bae and colleagues genotyped SNPs on CNV
regions for the CNVs identification. They found out 597
SNP markers with a multiallelic CNV genotype, known as
the common deletion polymorphism, within the CNV
region. Among 597 CNV markers, CNV region around
rs1242541 (nearest gene: SEL1L) showed the most signif-
icant association with the risk of SAH [46].
In 2010, they executed the first genome-wide association
study to investigate the relationship between common
CNVs and SAH. They hypothesized that CNVs can predict
the risk of SAH [47]. The authors identified a total of 4.574
CNVs from a Japanese population sample (n = 473) and
discovered 1.644 unique CNV regions containing 1.232
genes. The researchers carried out a genome-wide CNV
association analysis using a logistic regression model,
controlling for age and sex, to determine the association
between the identified CNVs and the risk of SAH in 187
CNVs with frequency[1 %. Interestingly, two CNV
regions, deletion 4q31.3 and duplication 10p15.1 have been
significantly associated with the risk of SAH. In the case of
chr4:153210505–153212191, the frequency of deletion in
the patients group was higher than that in the control group.
This result suggests that the deletion allele may be a risk
factor for SAH. In the case of chr10:6265006–6267388, the
frequency of duplication in the patients group was higher
than that in the control group. This latter finding indicates
that the increase in copy number in the region may influ-
ence the onset of SAH. Unlike their previous work, in this
study, no significant association has been detected between
CNV region around rs1242541 and the risk of SAH.
Probably, these discrepancies in the results may be due to
the fact that this last study was conducted at a larger scale.
Finally, investigations on the association between CNVs
and intracerebral hemorrhage (ICH) have never been
reported in the literature.
Discussion
Several factors may increase the risk of stroke, including
genetic ones, and in particular, CNVs. Even if the role of
CNVs in the genetic etiology of stroke is not yet well
established, there is an increasing interest in CNVs because
of their usefulness as a powerful tool in understanding the
genetic basis of numerous diseases.
Until now, there are a relatively few association studies
between CNVs and stroke. Some studies concluded that
rare CNVs may contribute to the pathogenesis of stroke,
1902 Neurol Sci (2016) 37:1895–1904
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while other studies detected no significant association
between specific CNVs and the risk of stroke. These
seemingly contradictory data can arise, because in most
studies, the method used for detecting CNVs was SNP-
microarray. To confirm an unequivocally association
between CNVs and stroke and extend the current findings,
it would be desirable to use another methodology to detect
smaller CNVs or CNVs in genomic regions poorly covered
by this technique, for instance, CGH-array. In addition,
more duplications are missed by SNP-based array and
sequencing than by CGH-array and SNP-array, which have
limited ability to detect single-exon CNVs due to the dis-
tribution of SNPs across the genome. Currently, CGH-ar-
ray is the most sensitive tool for the research of CNVs.
Another strategy to improve the detecting of CNVs would
be that to combine SNP-microarray and CGH-array into
one platform providing a genetic screening in a more
efficient manner.
Furthermore, screening of CNVs in a suitable number of
patients would be required to confirm unambiguously the
association between CNVs and risk for stroke.
It is clear that the discovery of disease-associated CNVs
will lead to improvements in clinical genetic diagnosis and
genetic counseling. This will not only help to make more
appropriate diagnosis but may help to design treatments
which could be allocated according to genetic etiology
rather than meeting strict diagnostic criteria set for each
separate disorder. Therefore, the identification of CNVs
could lead to personalized medical treatments which would
be targeted for each patient and his genome, and could,
therefore, improve treatment success.
Finally, as patients with shared genetic etiologies of
stroke will be identified, studies of genotype–phenotype
correlation, natural history, and therapeutic response to
specific drugs can be performed, which will lead to
improved long-term care and outcomes for patients.
In light of these observations, further studies will be
required to clarify how CNVs may affect an individual’s
susceptibility to stroke, to confirm the associations in larger
populations, and to know if there are some association
between CNVs and the different subtypes of stroke.
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